<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.1 20050630//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName journalpublishing.dtd?>
<?SourceDTD.Version 2.1?>
<?ConverterInfo.XSLTName jp2nlmx2.xsl?>
<?ConverterInfo.Version 2?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Bioinformation</journal-id>
    <journal-id journal-id-type="publisher-id">Bioinformation</journal-id>
    <journal-title-group>
      <journal-title>Bioinformation</journal-title>
    </journal-title-group>
    <issn pub-type="epub">0973-2063</issn>
    <publisher>
      <publisher-name>Biomedical Informatics</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">3163931</article-id>
    <article-id pub-id-type="publisher-id">97320630007038</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Software</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>ValFold: Program for the aptamer truncation process</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Akitomi</surname>
          <given-names>Joe</given-names>
        </name>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Kato</surname>
          <given-names>Shintaro</given-names>
        </name>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Yoshida</surname>
          <given-names>Yoshihito</given-names>
        </name>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Horii</surname>
          <given-names>Katsunori</given-names>
        </name>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Furuichi</surname>
          <given-names>Makio</given-names>
        </name>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Waga</surname>
          <given-names>Iwao</given-names>
        </name>
        <xref ref-type="corresp" rid="COR1">*</xref>
      </contrib>
      <aff>VALWAY Technology Center, NEC Soft, Ltd., 1-18-7, Shinkiba Koto-ku, Tokyo 136-8627, Japan</aff>
    </contrib-group>
    <author-notes>
      <corresp id="COR1"><label>*</label>Iwao Waga: <email>wagaiwao@mxc.nes.nec.co.jp</email></corresp>
    </author-notes>
    <pub-date pub-type="collection">
      <year>2011</year>
    </pub-date>
    <pub-date pub-type="epub">
      <day>20</day>
      <month>8</month>
      <year>2011</year>
    </pub-date>
    <volume>7</volume>
    <issue>1</issue>
    <fpage>38</fpage>
    <lpage>40</lpage>
    <history>
      <date date-type="received">
        <day>12</day>
        <month>5</month>
        <year>2011</year>
      </date>
      <date date-type="accepted">
        <day>21</day>
        <month>6</month>
        <year>2011</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2011 Biomedical Informatics</copyright-statement>
      <copyright-year>2011</copyright-year>
      <license license-type="open-access">
        <license-p>This is an open-access article, which permits unrestricted use, distribution, and reproduction in any medium, 
		for non-commercial purposes, provided the original author and source are credited.</license-p>
      </license>
    </permissions>
    <abstract>
      <p>DNA or RNA aptamers have gained attention as the next generation antibody-like molecules for medical or diagnostic use.
Conventional secondary structure prediction tools for nucleic acids play an important role to truncate or minimize sequence, or
introduce limited chemical modifications without compromising or changing its binding affinity to targets in the design of
improved aptamers selected by Systematic Evolution of Ligands by EXponential enrichment (SELEX). We describe a novel
software package, ValFold, capable of predicting secondary structures with improved accuracy based on unique aptamer
characteristics. ValFold predicts not only the canonical Watson-Crick pairs but also G-G pairs derived from G-quadruplex (known
structure for many aptamers) using the stem candidate selection algorithm.</p>
      <sec id="sb1e">
        <title>Availability</title>
        <p>The database is available for free at <ext-link ext-link-type="uri" xlink:href="http://code.google.com/p/valfold/">http://code.google.com/p/valfold/</ext-link></p>
      </sec>
    </abstract>
    <kwd-group>
      <kwd>aptamer</kwd>
      <kwd>SELEX</kwd>
      <kwd>aptamer truncation</kwd>
      <kwd>secondary structure prediction</kwd>
    </kwd-group>
  </article-meta>
</front>
<body>
  <sec id="s1">
    <title>Background</title>
    <p>Aptamers are well-known nucleic acid molecules that tightly
bind to their targets by recognizing their three-dimensional
structures. Aptamers are usually obtained by the SELEX
(Systematic Evolution of Ligands by EXponential enrichment)
process [<xref ref-type="bibr" rid="R01">1</xref>,
<xref ref-type="bibr" rid="R02">2</xref>]. 
The aptamer sequence data show the following
four unique characteristics compared to the usual genomic,
RNA or other natural sequences analysis. The first is that the
length of each aptamer is usually shorter than 150 bases. The
second is that the sequence data sets from one selection process
usually consist of multiple sequence groups. The third unique
characteristic was that at least two structurally different forms
are predicted depending on the existence of their targets which
is well-known in riboswitch studies. Riboswitches are one of
the natural aptamers found in micro-organisms and plants 
[<xref ref-type="bibr" rid="R03">3</xref>].
The fourth is that multiple aptamer sequences usually contain
some redundant motifs. Experimental truncation approaches of
aptamers retaining the redundant sequence part could
sometimes successfully minimize an aptamer length without
significant loss of its binding activity 
[<xref ref-type="bibr" rid="R04">4</xref>]. It is worthwhile in
considering the third and the forth characteristics of aptamers
to verify the strategy of a secondary structure prediction
algorithm. The widely-used secondary structure prediction
software for RNA are well established for the universal
prediction of RNA molecules, but they have no capability to
predict the structural changes between the free-form and the
target molecule-bound form, which, we think, are important
aspects when the aptamer secondary structure is predicted.</p>
  </sec>
  <sec sec-type="methods" id="s2">
    <title>Methodology</title>
    <p>The ValFold program is developed using Java (JDK 1.6.0). The
mainstream of ValFold is a secondary structure prediction
algorithm to minimize the free energy. We expand this
algorithm to predict the G-quartet structure, which is generally
known as the unique structure of the telomere part of all
chromosomes [<xref ref-type="bibr" rid="R05">5</xref>], and also reported in many aptamers binding
to target molecules [<xref ref-type="bibr" rid="R06">6</xref>]. ValFold algorithm is based on the
optimization concept for all of the stem candidate
combinations. It also predicts the G-quartet structure because
the G-quartet structure candidate list is combined with the stem
candidate list at the same time. Each G-quartet structure
candidate has a report with Gibbs free energy parameter 
[<xref ref-type="bibr" rid="R07">7</xref>].
The ValFold algorithm process uses this energy parameter as an
indicator to find out the G-quartet structure candidates or the
usual stem candidates. The “CastOff” function is a characteristic
feature of ValFold. Aptamers are generally known to bind to
target molecules on single stranded regions known as “bulge”
or “loop” [<xref ref-type="bibr" rid="R08">8</xref>]. 
CastOff uses this hypothetical feature in aptamers
to predict the aptamer binding motif from single sets of SELEX
sequences.</p>
    <p>The practical process of ValFold algorithm is as follows 
(<xref ref-type="fig" rid="F1">Figure 1A</xref>)
: First, the suboptimal secondary structures among all of the
sequence sets of SELEX process are predicted by main function
of ValFold (Step 1). A flowchart of this process is represented in
<xref ref-type="fig" rid="F2">Figure 2</xref>. All of 
the single stranded regions such as “bulge” or
“loop” candidates are extracted from the suboptimal secondary
structures, except for the primer compliment sequences (Step 2).
The maximum length of the motif candidates and the number
of allowed mismatches in the motif candidates are input for the
calculation process (Step 3). Then CastOff algorithm finds the
conserved scores for each of the motif candidates according to
the number of the motif conserved sequences. If one of the
single stranded region candidates possesses a motif candidate,
CastOff determines that the sequence is a conserved motif
candidate (Step 4). A flowchart of these steps 2 to 4 is
represented in <xref ref-type="fig" rid="F3">Figure 3</xref>.</p>
    <p>CastOff determines the highest scoring motif as the most
possible motif. The filtering of secondary structure candidates
with CastOff generates results including cases where the motif
candidates are found only in a bulge and loop structures.
Therefore, it is possible to select the aptamer secondary
structures that can bind with the target molecules as a binding
conformation. If the candidate motif is found on “bulge” or
“loop” structure on the binding conformation, it is worthwhile
to attempt to retain those regions in a truncate aptamer
candidates and subject for further binding assays by
researchers. The example is shown in <xref ref-type="fig" rid="F1">Figure 1C</xref>.</p>
  </sec>
  <sec id="s3">
    <title>Software Input and output</title>
    <p>ValFold supports FASTA format as an input. Users can add the
primer region information for each aptamer sequence to use the
CastOff function. Calculation results of ValFold are displayed
with GUI (<xref ref-type="fig" rid="F1">Figure 1B</xref>). 
<xref ref-type="fig" rid="F1">Figure 1B</xref> shows the result of a RNA
aptamer bound to sphingosylphosphorylcholine (SPC) shown
as an examples [<xref ref-type="bibr" rid="R09">9</xref>]. 
“UUA” was predicted as target binding
motif in the loop region in this example. The result was
subsequently validated as the truncated aptamer, m12, is shown
to bind SPC with good affinity (<xref ref-type="fig" rid="F1">Figure 1C</xref>).</p>
  </sec>
  <sec id="s4">
    <title>Caveat and future development</title>
    <p>We have developed the aptamer truncation program by using a
binding conformation prediction. The truncation strategy
worked very well in some cases such as SPC 
[<xref ref-type="bibr" rid="R09">9</xref>] and rabbit
immunoglobulin G [<xref ref-type="bibr" rid="R10">10</xref>] aptamers which are based on 96 well
based sequencers. At this moment, ValFold does not support
large data sets from next-generation sequencing equipments
because the current version is computationally slow. So, we
need to develop the next version of ValFold to adapt the large
sequence data sets which will enable us to find better aptamers.</p>
  </sec>
</body>
<back>
  <ack>
    <p>The authors thank Drs. Penmetcha K. R. Kumar, Hiroshi
Mizuno, Fumiko Nishikawa and Satoshi Nishikawa for
scientific discussions. The development of ValFold was partially
supported by the Bio-oriented Technology Research
Advancement Institution (BRAIN).</p>
  </ack>
  <fn-group>
    <fn id="FN1" fn-type="other">
      <p><bold>Citation:</bold>Akitomi <italic>et al</italic>, Bioinformation 7(1): 38-40 (2011)</p>
    </fn>
  </fn-group>
  <ref-list>
    <title>References</title>
    <ref id="R01">
      <label>1</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>C</surname>
            <given-names>Tuerk</given-names>
          </name>
          <name>
            <surname>L</surname>
            <given-names>Gold</given-names>
          </name>
        </person-group>
        <source>Science</source>
        <year>1990</year>
        <volume>249</volume>
        <fpage>505</fpage>
        <pub-id pub-id-type="pmid">2200121</pub-id>
      </element-citation>
    </ref>
    <ref id="R02">
      <label>2</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>AD</surname>
            <given-names>Ellington</given-names>
          </name>
          <name>
            <surname>JW</surname>
            <given-names>Szostak</given-names>
          </name>
        </person-group>
        <source>Nature</source>
        <year>1990</year>
        <volume>346</volume>
        <fpage>818</fpage>
        <pub-id pub-id-type="pmid">1697402</pub-id>
      </element-citation>
    </ref>
    <ref id="R03">
      <label>3</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>E</surname>
            <given-names>Nudler</given-names>
          </name>
          <name>
            <surname>AS</surname>
            <given-names>Mironov</given-names>
          </name>
        </person-group>
        <source>Trends Biochem Sci</source>
        <year>2004</year>
        <volume>29</volume>
        <fpage>11</fpage>
        <pub-id pub-id-type="pmid">14729327</pub-id>
      </element-citation>
    </ref>
    <ref id="R04">
      <label>4</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>SD</surname>
            <given-names>Jayasena</given-names>
          </name>
        </person-group>
        <source>Clin Chem</source>
        <year>1999</year>
        <volume>45</volume>
        <fpage>1628</fpage>
        <pub-id pub-id-type="pmid">10471678</pub-id>
      </element-citation>
    </ref>
    <ref id="R05">
      <label>5</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>JR</surname>
            <given-names>Williamson</given-names>
          </name>
          <etal/>
        </person-group>
        <source>Cell</source>
        <year>1989</year>
        <volume>59</volume>
        <fpage>871</fpage>
        <pub-id pub-id-type="pmid">2590943</pub-id>
      </element-citation>
    </ref>
    <ref id="R06">
      <label>6</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>LC</surname>
            <given-names>Bock</given-names>
          </name>
          <etal/>
        </person-group>
        <source>Nature</source>
        <year>1992</year>
        <volume>355</volume>
        <fpage>564</fpage>
        <pub-id pub-id-type="pmid">1741036</pub-id>
      </element-citation>
    </ref>
    <ref id="R07">
      <label>7</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>N</surname>
            <given-names>Sugimoto</given-names>
          </name>
          <etal/>
        </person-group>
        <source>Nucleosides &amp; Nucleotides</source>
        <year>1996</year>
        <volume>15</volume>
        <fpage>559</fpage>
      </element-citation>
    </ref>
    <ref id="R08">
      <label>8</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>T</surname>
            <given-names>Hermann</given-names>
          </name>
          <name>
            <surname>DJ</surname>
            <given-names>Patel</given-names>
          </name>
        </person-group>
        <source>Science</source>
        <year>2000</year>
        <volume>287</volume>
        <fpage>820</fpage>
        <pub-id pub-id-type="pmid">10657289</pub-id>
      </element-citation>
    </ref>
    <ref id="R09">
      <label>9</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>K</surname>
            <given-names>Horii</given-names>
          </name>
          <etal/>
        </person-group>
        <source>Molecules</source>
        <year>2010</year>
        <volume>15</volume>
        <issue>8</issue>
        <fpage>5742</fpage>
        <pub-id pub-id-type="pmid">20729797</pub-id>
      </element-citation>
    </ref>
    <ref id="R10">
      <label>10</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Y</surname>
            <given-names>Yoshida</given-names>
          </name>
          <etal/>
        </person-group>
        <source>Anal Biochem</source>
        <year>2008</year>
        <volume>375</volume>
        <issue>2</issue>
        <fpage>217</fpage>
        <pub-id pub-id-type="pmid">18252191</pub-id>
      </element-citation>
    </ref>
    <ref id="R11">
      <label>11</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>K</surname>
            <given-names>Han</given-names>
          </name>
          <etal/>
        </person-group>
        <source>Nucleic Acids Res</source>
        <year>2003</year>
        <volume>31</volume>
        <issue>13</issue>
        <fpage>3432</fpage>
        <pub-id pub-id-type="pmid">12824341</pub-id>
      </element-citation>
    </ref>
    <ref id="R12">
      <label>12</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>DH</surname>
            <given-names>Mathews</given-names>
          </name>
          <etal/>
        </person-group>
        <source>J Mol Biol</source>
        <year>1999</year>
        <volume>288</volume>
        <issue>5</issue>
        <fpage>911</fpage>
        <pub-id pub-id-type="pmid">10329189</pub-id>
      </element-citation>
    </ref>
    <ref id="R13">
      <label>13</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>JJr</surname>
            <given-names>SantaLucia</given-names>
          </name>
        </person-group>
        <source>Proc Natl Acad Sci U S A</source>
        <year>1998</year>
        <volume>95</volume>
        <fpage>1460</fpage>
        <pub-id pub-id-type="pmid">9465037</pub-id>
      </element-citation>
    </ref>
  </ref-list>
</back>
<floats-group>
  <fig id="F1" position="float">
    <label>Figure 1</label>
    <caption>
      <p>Truncation procedure of ValFold. Secondary
structures were drawn by using PseudoViewer 
[<xref ref-type="bibr" rid="R11">11</xref>], Turner
model [<xref ref-type="bibr" rid="R12">12</xref>] and SantaLucia model 
[<xref ref-type="bibr" rid="R13">13</xref>] are used for the
calculation of free energies of RNA and DNA aptamers.</p>
    </caption>
    <graphic xlink:href="97320630007038F1"/>
  </fig>
  <fig id="F2" position="float">
    <label>Figure 2</label>
    <caption>
      <p>Flowchart of ValFold 1 (Figure 1A Step 1).</p>
    </caption>
    <graphic xlink:href="97320630007038F2"/>
  </fig>
  <fig id="F3" position="float">
    <label>Figure 3</label>
    <caption>
      <p>Flowchart of ValFold 2 (Figure 1A Step 2, 3, 4).</p>
    </caption>
    <graphic xlink:href="97320630007038F3"/>
  </fig>
</floats-group>
